These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31841869)

  • 61. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125.
    Kawai R; Lemaire M; Steimer JL; Bruelisauer A; Niederberger W; Rowland M
    J Pharmacokinet Biopharm; 1994 Oct; 22(5):327-65. PubMed ID: 7791036
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Development of Physiologically Based Organ Models to Evaluate the Pharmacokinetics of Drugs in the Testes and the Thyroid Gland.
    Pilari S; Gaub T; Block M; Görlitz L
    CPT Pharmacometrics Syst Pharmacol; 2017 Aug; 6(8):532-542. PubMed ID: 28571120
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cross species extrapolation of the disruption of thyroid hormone synthesis by oxyfluorfen using in vitro data, physiologically based pharmacokinetic (PBPK), and thyroid hormone kinetics models.
    Decrane R; Stoker T; Murr A; Ford J; El-Masri H
    Curr Res Toxicol; 2023; 5():100138. PubMed ID: 38074188
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.
    Zhang Z; Unadkat JD
    Drug Metab Dispos; 2017 Aug; 45(8):939-946. PubMed ID: 28049636
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Construction of a physiologically based pharmacokinetic model of paclobutrazol and exposure estimation in the human body.
    Li X; Lian T; Su B; Liu H; Wang Y; Wu X; He J; Wang Y; Xu Y; Yang S; Li Y
    Toxicology; 2024 Jun; 505():153841. PubMed ID: 38796053
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Linking physiologically-based pharmacokinetic and genome-scale metabolic networks to understand estradiol biology.
    Sier JH; Thumser AE; Plant NJ
    BMC Syst Biol; 2017 Dec; 11(1):141. PubMed ID: 29246152
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Estimation of placental and lactational transfer and tissue distribution of atrazine and its main metabolites in rodent dams, fetuses, and neonates with physiologically based pharmacokinetic modeling.
    Lin Z; Fisher JW; Wang R; Ross MK; Filipov NM
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):140-58. PubMed ID: 23958493
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
    Abdullah R; Alhusainy W; Woutersen J; Rietjens IM; Punt A
    Food Chem Toxicol; 2016 Jun; 92():104-16. PubMed ID: 27016491
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.
    Kedderis GL; Lipscomb JC
    Toxicol Ind Health; 2001 Jun; 17(5-10):315-21. PubMed ID: 12539878
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure.
    Leclerc E; Hamon J; Legendre A; Bois FY
    Toxicol In Vitro; 2014 Oct; 28(7):1230-41. PubMed ID: 24929096
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Kinetic modeling of β-chloroprene metabolism: Probabilistic in vitro-in vivo extrapolation of metabolism in the lung, liver and kidneys of mice, rats and humans.
    Yang Y; Himmelstein MW; Clewell HJ
    Toxicol In Vitro; 2012 Sep; 26(6):1047-55. PubMed ID: 22543297
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of a Physiologically Based Pharmacokinetic (PBPK) Model for Inorganic Arsenic Exposure Using Data from Two Diverse Human Populations.
    El-Masri HA; Hong T; Henning C; Mendez W; Hudgens EE; Thomas DJ; Lee JS
    Environ Health Perspect; 2018 Jul; 126(7):077004. PubMed ID: 30024383
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.
    Munir A; Azam S; Fazal S; Bhatti AI
    J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
    Li M; Zou P; Tyner K; Lee S
    AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Integrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment-A case study of troglitazone.
    Yu L; Li H; Zhang C; Zhang Q; Guo J; Li J; Yuan H; Li L; Carmichael P; Peng S
    Environ Toxicol Pharmacol; 2020 Feb; 74():103296. PubMed ID: 31783317
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Repeated dose (28 days) oral toxicity study of flutamide in rats, based on the draft protocol for the 'Enhanced OECD Test Guideline 407' for screening for endocrine-disrupting chemicals.
    Toyoda K; Shibutani M; Tamura T; Koujitani T; Uneyama C; Hirose M
    Arch Toxicol; 2000 May; 74(3):127-32. PubMed ID: 10876997
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats.
    Krishnan K; Crouse LC; Bazar MA; Major MA; Reddy G
    J Appl Toxicol; 2009 Oct; 29(7):629-37. PubMed ID: 19629953
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Linking internal dosimetries of the propyl metabolic series in rats and humans using physiologically based pharmacokinetic (PBPK) modeling.
    Smith JN; Tyrrell KJ; Smith JP; Weitz KK; Faber W
    Regul Toxicol Pharmacol; 2020 Feb; 110():104507. PubMed ID: 31669189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.